Zedge, Inc.: Zedge's Tapedeck Adds Betty Wright's Catalog in Agreement With the Late Soul Legend's Estate

Zedge, Inc. (NYSE American: ZDGE) said Tapedeck has signed an agreement with the estate of Betty Wright to add her catalog to the platform, available now and timed to Juneteenth. The company says Tapedeck pays rights holders 80% of fan spending; for Wright’s catalog, 80 cents of each dollar goes to the estate. Tapedeck launched on iOS in the U.S. in fall 2025.

Original reporting
Published Jun 17, 2026, 8:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 18, 2026, 12:25 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Zedge, Inc.: Zedge's Tapedeck Adds Betty Wright's Catalog in Agreement With the Late Soul Legend's Estate — source image
Decision brief

The 30-second read

$ZDGEBullishLow
01

Why it matters

The Betty Wright estate agreement adds a high-recognition legacy catalog and reinforces Tapedeck’s positioning around artist ownership and fair payout, potentially improving conversion and licensing momentum.

02

Market read

A new, company-announced licensing deal for Tapedeck’s catalog content, but with no quantified financial impact.

03

What to watch

Investors may focus more on Tapedeck’s user growth, retention, and take-rate economics than on individual catalog additions; the article doesn’t provide those KPIs.

Relevance 5/10Novelty 4/10Timing: available now; announcement dated Juneteenth (June 17, 2026)

Background

Tapedeck is Zedge’s pay-as-you-go music streaming/download service with a penny-per-play floor and no subscription fees; rights holders receive 80% of fan spending.

Company-level read

Ticker impact

$ZDGEBullishMedium confidence
Context

Zedge announced a Tapedeck agreement with Betty Wright’s estate to add her catalog to the platform, available now and timed to Juneteenth.

Expected impact

Likely limited near-term impact unless investors view the deal as evidence of accelerating licensing traction.

Evidence & confidence

The disclosure is company-specific (new licensing agreement) but lacks deal size, expected revenue, or subscriber/streaming targets; it reads as promotional product traction rather than a quantified earnings catalyst.

Market effects

Highlights a pay-as-you-go, rights-holder-favorable streaming model that could support further licensing discussions for niche/legacy catalogs.

No clear regional demand signal beyond a Miami launch event.

International expansion is mentioned, but this specific catalog deal is not described as region-specific.

Counterpoint

Without disclosed economics (advance, minimum guarantees, expected streams), the market may treat this as incremental content marketing rather than a material revenue driver.

Key entities

  • Zedge, Inc.

    Operator of Tapedeck and creator communities; announced the Betty Wright estate licensing agreement.

  • Tapedeck

    Zedge’s pay-as-you-go music streaming/download service with 80% rights-holder payout.

  • Betty Wright estate

    Licensing counterparty for Betty Wright’s catalog on Tapedeck.

Related articles

$ZDGEMed

Zedge Reports Third Quarter Fiscal 2026 Results

Zedge, Inc. (ZDGE) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ea029448101ex99-1.htm EARNINGS RELEASE, DATED JUNE 11, 2026, REPORTING THE RESULTS OF OPERATIONS FOR ZEDGE, INC.'S FISCAL QUARTER ENDED APRIL 30, 2026 Exhibit 99.1 Zedge Reports Third Quarter Fiscal 2026 Results Subscription revenue increased 32%, and active subscriptio

$PFEMedAI 8/10

Pfizer Inc details 61% tilrekimig Phase 2 response

Pfizer reported Phase 2 results for tilrekimig in atopic dermatitis, with a 61% EASI-75 response rate at a monthly 200 mg dose, compared to 9.1% on placebo. The study is ongoing, with Phase 3 trials initiated. Pfizer shares closed at $28.52 on Sept. 30, before the detailed data release.

$PFEHighAI 8/10

Pfizer's Tilrekimig Shows Significant Skin Clearance in Phase 2

Pfizer's Phase 2 study of tilrekimig (PF-07275315) in moderate-to-severe atopic dermatitis met its primary endpoint, showing significant skin clearance at Week 16. The study reported EASI-75 rates of 62.5% for 450 mg Q2W and 58.5%-61.0% for 200-400 mg Q4W doses, compared to 19.9%-9.1% for placebo. Tilrekimig was well-tolerated, with no dose-dependent safety signals. Pfizer has initiated Phase 3 trials for tilrekimig in atopic dermatitis, asthma, and COPD.

$GOOGMed

Key facts: Alphabet Inc. Class C unveils Gemini 4 Argon; $260M calls

Alphabet Inc. Class C (GOOG) launched Gemini 4 Argon, claiming higher performance. The company saw $260M in options calls, stock up 2.7%. GOOG canceled Gemini 3.5 Pro release, signed AI safety pact, and faces lawmaker inquiries. Cloud backlog nears $1.688T in Q2 2026. CEO Pichai emphasized cost advantages. Brazil betting promos banned, certificates revoked.